Garczorz Wojciech, Kosowska Agnieszka, Francuz Tomasz
Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-055 Katowice, Poland.
Cancers (Basel). 2024 Jan 10;16(2):299. doi: 10.3390/cancers16020299.
Diabetes is one of the leading chronic conditions worldwide, and breast cancer is the most prevalent cancer in women worldwide. The linkage between diabetes and its ability to increase the risk of breast cancer should always be analyzed in patients. This review focuses on the impact of antihyperglycemic therapy in breast cancer patients. Patients with diabetes have a higher risk of developing cancer than the general population. Moreover, diabetes patients have a higher incidence and mortality of breast cancer. In this review, we describe the influence of antidiabetic drugs from insulin and metformin to the current and emerging therapies, incretins and SGLT-2 inhibitors, on breast cancer prognosis. We also emphasize the role of obesity and the metastasis process in breast cancer patients who are treated with antidiabetic drugs.
糖尿病是全球主要的慢性疾病之一，而乳腺癌是全球女性中最常见的癌症。对于患者而言，应始终分析糖尿病及其增加乳腺癌风险的能力之间的联系。本综述聚焦于降糖治疗对乳腺癌患者的影响。糖尿病患者患癌风险高于普通人群。此外，糖尿病患者的乳腺癌发病率和死亡率更高。在本综述中，我们描述了从胰岛素和二甲双胍到当前及新兴疗法、肠促胰岛素和钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂等抗糖尿病药物对乳腺癌预后的影响。我们还强调了肥胖以及转移过程在接受抗糖尿病药物治疗的乳腺癌患者中的作用。
